U.S. Markets closed

Synthetic Biologics, Inc. (SYN)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.4848-0.0165 (-3.2914%)
At close: 3:59PM EDT

0.4999 0.02 (3.11%)
After hours: 4:44PM EDT

People also watch
ZIOPIDRAFCSCCRMDSGYP

Synthetic Biologics, Inc.

9605 Medical Center Drive
Suite 270
Rockville, MD 20850
United States
301-417-4364
http://www.syntheticbiologics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees28

Key Executives

NameTitlePayExercisedAge
Mr. Jeffrey Lucero Riley MBACEO, Pres & Director1.03MN/A54
Mr. Steven A. Shallcross CPACFO, Treasurer & Sec.601.18kN/A56
Dr. Michael Kaleko M.D., Ph.D.Sr. VP of R&DN/AN/AN/A
Dr. Joseph A. Sliman M.D., MPHChief Medical OfficerN/AN/A44
Dr. Raymond D. Stapleton Jr., Ph.D.Sr. VP of ManufacturingN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates in Phase III development include SYN-010, which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase) that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Corporate Governance

Synthetic Biologics, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.